Abstract
The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is arare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancercells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define pro-teomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the pro-tein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of post-translational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniquesallow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spec-trometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. Weintroduce the p53 protein as an illustration of the complexity of post-translational m odifications that may affect one highlyconnected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and statusof signal transduction systems of the malignancy.
Keywords: p53, AML, diagnosis, therapy, signaling networks, two-dimensional electrophoresis
Current Pharmaceutical Biotechnology
Title: Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia
Volume: 7 Issue: 3
Author(s): Nina Anensen, Ingvild Haaland, Clive D'Santos, Werner Van Belle and Bjorn Tore Gjertsen
Affiliation:
Keywords: p53, AML, diagnosis, therapy, signaling networks, two-dimensional electrophoresis
Abstract: The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is arare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancercells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define pro-teomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the pro-tein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of post-translational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniquesallow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spec-trometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. Weintroduce the p53 protein as an illustration of the complexity of post-translational m odifications that may affect one highlyconnected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and statusof signal transduction systems of the malignancy.
Export Options
About this article
Cite this article as:
Anensen Nina, Haaland Ingvild, D'Santos Clive, Werner Van Belle and Bjorn Tore Gjertsen , Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia, Current Pharmaceutical Biotechnology 2006; 7 (3) . https://dx.doi.org/10.2174/138920106777549731
DOI https://dx.doi.org/10.2174/138920106777549731 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Current Medicinal Chemistry Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology TH2 Cytokines and Associated Transcription Factors as Therapeutic Targets in Asthma
Current Drug Targets - Inflammation & Allergy Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Dimethyl Sulfoxide as an Excitatory Modulator and its Possible Role in Cancer Pain Management
Inflammation & Allergy - Drug Targets (Discontinued) Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Therapeutic Options for Transfusion Related Acute Lung Injury; the Potential of the G2A Receptor
Current Pharmaceutical Design CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Diagnostic Methods in the Detection of Prostate Cancer: Prospective Observational Study
Current Medical Imaging Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Camptothecins and Lung Cancer: Improved Delivery Systems by Aerosol
Current Cancer Drug Targets Inhibition of Raf Kinase in the Treatment of Acute Myeloid Leukemia
Current Pharmaceutical Design Meet the Associate Editor
MicroRNA